Frontotemporal Dementia

Frontotemporal Dementia (FTD)

Introduction

Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. It is the second most common cause of early-onset dementia after Alzheimer's Disease, typically affecting individuals between 45-65 years of age. FTD encompasses a spectrum of clinical syndromes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA) variants, each with distinct clinical presentations and underlying pathologies. [@heneka2023]

Unlike Alzheimer's Disease, which primarily affects memory, FTD often presents with changes in personality, behavior, and language abilities, reflecting the regional distribution of neurodegeneration in the frontal and temporal cortices. The disease is pathologically heterogeneous, with approximately 50% of cases showing [tau protein](/proteins/tau) inclusions (FTLD-tau) and 45% showing TDP-43 inclusions (FTLD-TDP), while a smaller subset exhibits FUS pathology. [@gao2024]

Overview

Frontotemporal Dementia represents a clinically and pathologically diverse group of disorders that result from degeneration of the anterior cerebral hemispheres. The estimated prevalence is 10-20 per 100,000 individuals aged 45-64, making it a significant cause of early-onset neurodegenerative dementia. [@li2024]

Frontotemporal Dementia (FTD)

Introduction

Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. It is the second most common cause of early-onset dementia after Alzheimer's Disease, typically affecting individuals between 45-65 years of age. FTD encompasses a spectrum of clinical syndromes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA) variants, each with distinct clinical presentations and underlying pathologies. [@heneka2023]

Unlike Alzheimer's Disease, which primarily affects memory, FTD often presents with changes in personality, behavior, and language abilities, reflecting the regional distribution of neurodegeneration in the frontal and temporal cortices. The disease is pathologically heterogeneous, with approximately 50% of cases showing [tau protein](/proteins/tau) inclusions (FTLD-tau) and 45% showing TDP-43 inclusions (FTLD-TDP), while a smaller subset exhibits FUS pathology. [@gao2024]

Overview

Frontotemporal Dementia represents a clinically and pathologically diverse group of disorders that result from degeneration of the anterior cerebral hemispheres. The estimated prevalence is 10-20 per 100,000 individuals aged 45-64, making it a significant cause of early-onset neurodegenerative dementia. [@li2024]

FTD is often inherited in an autosomal dominant pattern in 20-30% of cases, with three major causal genes: [MAPT](/proteins/mapt-protein) (microtubule-associated protein tau), [GRN](/proteins/grn-protein) (progranulin), and [C9orf72](/proteins/c9orf72-protein) (chromosome 9 open reading frame 72). These genetic forms typically have earlier onset and may present with overlapping features with ALS in [C9orf72](/entities/c9orf72) carriers. [@bennett2024]

The clinical syndromes within the FTD spectrum include:

• Behavioral Variant FTD (bvFTD): Characterized by disinhibition, apathy, loss of empathy, compulsivity, and dietary changes
• Semantic Variant Primary Progressive Aphasia (svPPA): Progressive loss of word and object meaning
• Nonfluent/agrammatic Variant PPA (nfvPPA): Grammatical errors and effortful speech
• Logopenic Variant PPA (lvPPA): Word-finding pauses and memory lapses

Epidemiology

Frontotemporal dementia accounts for 10-20% of all dementia cases and up to 50% of dementia cases with onset before 65 years. [@li2024] The estimated prevalence is:

• Age-specific: 10-20 per 100,000 in individuals aged 45-64 years
• Gender distribution: Slight male predominance (1.5:1) in bvFTD
• Onset: Typically 45-65 years, though ranges from 20-80 years
• Survival: Median survival 6-11 years from symptom onset

Pathology

FTD is pathologically classified into several subtypes based on the protein inclusions observed post-mortem: [@gao2024]

FTLD-TDP (TDP-43 Proteinopathy)

Approximately 45% of FTD cases show inclusions of the transactive response DNA-binding protein 43 (TDP-43). This subtype is strongly associated with [GRN](/proteins/grn-protein) mutations and [C9orf72](/proteins/c9orf72-protein) expansions. TDP-43 pathology is also found in 95% of ALS cases, explaining the clinical overlap between FTD and ALS. [@heneka2023]

FTLD-TDP Subtypes:

• Type A: Neuronal intranuclear inclusions (NII) and neuronal cytoplasmic inclusions (NCI); associated with [GRN](/proteins/grn-protein) mutations
• Type B: Diffuse NCI without NII; associated with [C9orf72](/proteins/c9orf72-protein) expansions
• Type C: NCI predominant; typical of semantic variant PPA
• VCP-associated: Inclusion body myopathy with Paget disease of bone (IBMPFD) and FTD; [VCP](/proteins/vcp-p97) mutations cause TDP-43 pathology

FTLD-Tau

Approximately 50% of FTD cases show [tau protein](/proteins/tau) inclusions, often associated with [MAPT](/proteins/mapt-protein) mutations. Tau pathology in FTD includes Pick bodies (Pick's disease), corticobasal degeneration patterns, and progressive supranuclear palsy patterns. [@gao2024]

FTLD-Tau Subtypes:

• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration): 4R tau filaments, astrocytic plaques, cortical and basal ganglia involvement
• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy):PSP Richardson syndrome, 4R tau filaments, brainstem involvement
• Pick's Disease: 3R tau filaments, Pick bodies, focal frontal/temporal atrophy
• Argyrophilic Grain Disease (AGD): [Argyrophilic grain disease](/diseases/argyrophilic-grain-disease), 4R tau, mild cognitive impairment
• Primary Age-Related Tauopathy (PART): 3R+4R tau, older adults, limbic predominant

FTLD-FUS

Approximately 5-10% of FTD cases show FUS (fused in sarcoma) inclusions, typically in younger patients with severe behavioral symptoms. [@gao2024] FTLD-FUS includes:

• Atypical FTLD with FUS inclusions (aFTLD): Younger onset, severe behavioral symptoms
• neuronal intermediate filament inclusion disease (NIFID): FUS + intermediate filament inclusions

FTLD Subtype Comparison

FTLD Subtype at a Glance

| Pathology | Protein | Key Inclusion | Typical Clinical | Primary Genes |
|-----------|---------|---------------|------------------|---------------|
| FTLD-Tau | Hyperphosphorylated tau | NFT, Pick bodies, astrocytic plaques | bvFTD, CBS, PSP, PPA | [MAPT](/proteins/mapt-protein) |
| FTLD-TDP | TDP-43 | NCI, NII, dystrophic neurites | bvFTD, svPPA, FTD-ALS | [GRN](/proteins/grn-protein), [C9orf72](/proteins/c9orf72-protein) |
| FTLD-FUS | FUS protein | FUS-positive inclusions | bvFTD (young onset) | Sporadic |
| FTLD-UPS | Ubiquitin (unknown) | Ub-positive, TDP/FUS-negative | FTD | CHMP2B |

Genetics

Major Causative Genes

| Gene | Protein | Inheritance | Pathology | Frequency |
|------|---------|------------|-----------|-----------|
| [MAPT](/proteins/mapt-protein) | Microtubule-associated protein tau | Autosomal dominant | FTLD-tau | ~10-20% of familial FTD |
| [GRN](/proteins/grn-protein) | Progranulin | Autosomal dominant | FTLD-TDP | ~5-10% of familial FTD |
| [C9orf72](/proteins/c9orf72-protein) | C9orf72 protein | Autosomal dominant | FTLD-TDP | ~10-20% of familial FTD |

MAPT Mutations

Over 50 pathogenic mutations in [MAPT](/proteins/mapt-protein) have been identified, primarily in the exon 10 splice site and coding regions affecting tau isoform composition. These mutations disrupt microtubule function and promote tau aggregation. MAPT mutations cause Pick's disease and other FTLD-tau subtypes. [@bennett2024]

GRN Mutations

Loss-of-function mutations in [GRN](/proteins/grn-protein) cause haploinsufficiency leading to reduced progranulin levels. Progranulin is a neurotrophic factor involved in lysosomal function, and its deficiency leads to TDP-43 aggregation. GRN carriers often present with bvFTD or CBS (corticobasal syndrome). [@adni]

C9orf72 Expansions

The hexanucleotide repeat expansion in [C9orf72](/proteins/c9orf72-protein) is the most common genetic cause of both FTD and ALS. Expansions of >30 repeats are pathogenic, with some carriers developing FTD, ALS, or both. This intrafamilial variability suggests important genetic or environmental modifiers. [@aftd]

Clinical Features

Behavioral Variant FTD (bvFTD)

The most common FTD subtype, characterized by: [@miller2024]

• Disinhibition: Socially inappropriate behavior, loss of manners
• Apathy: Loss of interest, initiative, and motivation
• Loss of empathy: Reduced social engagement and emotional responsiveness
• Compulsivity: Ritualistic behaviors, compulsions
• Dietary changes: Hyperphagia, preference for sweets

Primary Progressive Aphasia (PPA) Variants

[Semantic Variant PPA (svPPA)](/diseases/semantic-variant-ppa): Loss of word and object meaning, fluent speech with empty content, surface dyslexia. [@zhang2024]

[Nonfluent/agrammatic Variant PPA (nfvPPA): Effortful speech, grammatical errors, apraxia of speech. [@zhang2024]

[Logopenic Variant PPA (lvPPA): Word-finding pauses, sentence repetition deficits, often associated with Alzheimer's pathology. [@zhang2024]

Motor Syndromes

FTD often overlaps with motor neuron disease (especially in C9orf72 carriers) and corticobasal syndrome (CBS), reflecting shared underlying pathologies. [@heneka2023]

Diagnosis

Clinical Criteria

Diagnosis relies on clinical history, neuropsychological testing, and neuroimaging: [@wang2024]

Biomarkers

Emerging biomarkers aim to distinguish FTLD subtypes in vivo: [@jucker2024]

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Elevated in CSF and blood, reflects neuronal injury
• Genetic testing: Critical for family counseling and clinical trial enrollment
• PET ligands: Emerging tau and TDP-43 PET tracers in development

Neuroinflammatory Mechanisms

Neuroinflammation plays a critical role in FTD pathogenesis, with mounting evidence indicating that microglial activation contributes to disease progression. Post-mortem studies reveal extensive microglial proliferation in the frontal and temporal cortices of FTD patients, correlating with regions of neuronal loss. [@dickson2022]

Microglial Activation

[Microglia](/cell-types/microglia) are the brain's resident immune cells and become progressively activated in FTD: [@hogan2023]

• Morphological changes: Ramified microglia transition to amoeboid, activated forms
• Cytokine release: Pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α are elevated in post-mortem brain tissue and CSF
• Chronic activation: Sustained neuroinflammation leads to synaptic loss and neuronal damage
• PET imaging: TSPO PET shows increased microglial activation in living FTD patients

• TDP-43 pathology: Cytoplasmic TDP-43 inclusions can activate innate immune responses
• Protein aggregates: Tau oligomers and TDP-43 aggregates act as DAMPs (damage-associated molecular patterns)
• Synaptic debris: Synaptic loss releases molecules that activate microglia

Inflammasome Activation

The NLRP3 inflammasome has been implicated in FTD pathogenesis: [@rohrer2023]

• Activation triggers: Aβ, tau oligomers, and TDP-43 aggregates can activate NLRP3
• Caspase-1 activation: Leads to maturation of pro-inflammatory cytokines IL-1β and IL-18
• Therapeutic targeting: NLRP3 inhibitors (e.g., MCC950) are under investigation for FTD
• Genetic links: NLRP3 variants may modify disease progression in GRN carriers

Neuroimmune Crosstalk

Peripheral immune system alterations in FTD include: [@baker2006]

• Blood-brain barrier dysfunction: Increased permeability allows peripheral immune cell infiltration
• T cell infiltration: CD8+ cytotoxic T cells accumulate in affected brain regions
• Systemic inflammation: Elevated peripheral cytokines correlate with disease severity
• Astrocyte reactivity: GFAP elevation in plasma reflects astrocyte activation

Cellular and Molecular Mechanisms

Tau Propagation

Tau pathology in FTD spreads through prion-like mechanisms: [@dejesushernandez2011]

• Tau seeds: Pathological tau can template native tau into misfolded forms
• Network connectivity: Tau spreads along brain networks, correlating with clinical deficits
• Oligomeric intermediates: Toxic tau oligomers may be the primary pathogenic species
• Strain variation: Different tau strains may determine clinical phenotypes

TDP-43 Aggregation

The majority of FTD cases involve TDP-43 proteinopathy: [@rascovsky2011]

• Nuclear loss of function: TDP-43 mislocalizes from nucleus to cytoplasm
• RNA splicing defects: Loss of nuclear TDP-43 disrupts alternative splicing of critical neuronal transcripts
• Stress granules: TDP-43 accumulates in stress granules under cellular stress
• Liquid-liquid phase separation: Aberrant phase separation may drive aggregation

• Phosphorylation: Hyperphosphorylated TDP-43 forms cytoplasmic inclusions
• Ubiquitination: TDP-43 inclusions are ubiquitinated for degradation
• C-terminal fragments: Proteolytic cleavage generates aggregation-prone fragments

Synaptic Dysfunction

Synaptic loss precedes neuronal death in FTD: [@gornotempini2011]

• Presynaptic changes: Reduced synaptophysin and synapsin expression
• Postsynaptic alterations: NMDA receptor downregulation, PSD-95 loss
• Electrophysiological deficits: Long-term potentiation impairments in model systems
• Network dysfunction: Disrupted functional connectivity on fMRI

Autophagy-Lysosomal Pathway

Dysregulation of protein clearance pathways contributes to FTD: [@finger2023]

• Autophagy impairment: Reduced LC3-II conversion, p62 accumulation
• Lysosomal dysfunction: Cathepsin D activity reduced in affected regions
• GRN connection: Progranulin localizes to lysosomes, deficiency causes accumulation
• Ubiquitinated protein accumulation: p62 and ubiquitin-positive inclusions

Animal Models

Genetic Models

Transgenic mouse models have been developed for FTD research: [@boxer2024]

• MAPT models: P301S, P301L mutations recapitulate tau pathology
• GRN models: Grn knockout mice show TDP-43 pathology and neuroinflammation
• C9orf72 models: BAC transgenic mice model hexanucleotide repeat expansion

Limitations and Advances

Current models have provided valuable insights but have limitations: [@tsai2023]

• Species differences: Mouse models don't fully replicate human disease phenotypes
• Late onset: FTD models often show subtle phenotypes due to late disease onset
• Organoids: Human iPSC-derived brain organoids offer new research avenues
• AAV delivery: Viral-mediated gene delivery enables rapid model generation

Biomarkers

Fluid Biomarkers

Blood and CSF biomarkers for FTD diagnosis: [@clinicaltrialsgov]

| Biomarker | Source | Change in FTD | Clinical Utility |
|-----------|--------|---------------|------------------|
| NfL | CSF/Plasma | Elevated | Disease progression, trial endpoint |
| p-tau181 | CSF/Plasma | Variable | Distinguish from AD |
| p-tau217 | CSF/Plasma | Elevated in FTLD-tau | FTLD-tau detection |
| p-tau231 | CSF/Plasma | Elevated | Early FTLD-tau detection |
| NfH | CSF/Plasma | Elevated | Disease severity |
| GFAP | Plasma | Elevated in FTLD-TDP | Astroglial activation |
| Neurogranin | CSF | Elevated | Synaptic dysfunction |
| Progranulin | Plasma | Reduced (GRN carriers) | Genetic screening |
| YKL-40 | CSF/Plasma | Elevated | Neuroinflammation |

Biomarker utility by FTLD subtype:

• FTLD-TDP: Elevated NfL, GFAP, reduced progranulin (GRN carriers)
• FTLD-tau: Elevated p-tau181, p-tau217, p-tau231
• Distinguishing AD from FTD: p-tau217/tau181 ratio shows promise

Imaging Biomarkers

Neuroimaging markers for FTD: [@petersen2026]

• Structural MRI: Frontal/temporal atrophy pattern, asymmetric involvement
• FDG-PET: Hypometabolism in affected regions
• TAU PET: Elevated binding in FTLD-tau subtypes (e.g., CBD, PSP patterns)
• DTI: White matter tract degeneration
• Resting-state fMRI: Disrupted functional connectivity

Caregiver Resources and Support

FTD presents unique challenges for caregivers due to the young age of onset and behavioral symptoms: [@khalil2025]

Financial and Legal Planning

• Disability benefits: Social Security Disability Insurance (SSDI) for qualifying patients
• Long-term care insurance: Early planning important given disease progression
• Legal capacity: Advance directives and power of attorney while patient can participate
• Estate planning: Special needs trusts for dependent children

Caregiver Support Organizations

• AFTD (Association for Frontotemporal Degeneration): Resources and support groups
• Caregiver respite: Adult day programs, in-home respite services
• Behavioral management: Training for managing disinhibition and compulsions
• Young-onset dementia programs: Specialized services for early-onset patients

Practical Strategies

• Communication techniques: Simplified language, visual cues
• Environmental modifications: Safe home environment, wander prevention
• Routine establishment: Consistent daily schedules reduce anxiety
• Nutrition management: Addressing hyperphagia and food choices

Conclusion

Frontotemporal Dementia represents a heterogeneous group of neurodegenerative disorders characterized by frontal and temporal lobe degeneration. The disease's complexity, with multiple pathological subtypes (FTLD-tau, FTLD-TDP, FTLD-FUS) and distinct clinical syndromes (bvFTD, PPA variants), presents significant challenges for diagnosis and treatment. Recent advances in understanding the genetic basis ([MAPT](/proteins/mapt-protein), [GRN](/proteins/grn-protein), [C9orf72](/proteins/c9orf72-protein)) and molecular mechanisms (tau propagation, TDP-43 aggregation, neuroinflammation) have identified promising therapeutic targets. While disease-modifying therapies remain elusive, active clinical trials targeting tau aggregation, TDP-43 pathology, and neuroinflammation offer hope for future treatments. Comprehensive care addressing behavioral symptoms, caregiver support, and quality of life remains essential for managing FTD patients.

Treatment

Symptomatic Treatments

Currently no disease-modifying therapies exist. Management focuses on symptomatic treatment: [@karch2024]

Behavioral interventions:

• Structured routines and environmental modifications
• Caregiver education and support
• Behavioral redirection strategies

• SSRIs (sertraline, paroxetine): May reduce disinhibition and compulsions
• Antipsychotics (risperidone, olanzapine): For severe agitation (use with caution)
• Mood stabilizers (valproate, carbamazepine): May help impulsivity
• [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Generally not effective, may worsen behavioral symptoms

Emerging Therapies

Clinical trials targeting:

• [GRN](/proteins/grn-protein) haploinsufficiency: Progranulin replacement therapies
• [MAPT](/proteins/mapt-protein) aggregation: Tau aggregation inhibitors
• TDP-43 pathology: Antisense oligonucleotides (ASOs) for C9orf72
• Neuroinflammation: [Microglia](/cell-types/microglia) modulators

Clinical Trials

Active and Recent FTD Clinical Trials (2024-2026)

Active clinical trials for FTD include: [@neumann2023]

• GRN-targeted ASO trials (e.g., IONIS-ApoCRx): Phase 1/2 trials targeting GRN haploinsufficiency, measuring progranulin elevation
• MAPT ASO trials (BIIB080): Phase 2 trials reducing MAPT expression in bvFTD
• C9orf72-targeted ASO trials: Reducing toxic RNA foci and dipeptide repeat proteins
• Tau aggregation inhibitors (hydromethylthionine mesylate/LMTM): Phase 3 trials for FTLD-tau
• Anti-tau antibody trials: Semorinemab, Bepranemab for FTLD-tau subtypes
• Neuroinflammation trials: CSF1R antagonists (e.g., pexidartinib) for microglial modulation
• Neuroprotective trials: Antioxidants, neurotrophic factors

Clinical Trial Endpoints

Current trial endpoints being validated:

• Primary: Clinical dementia rating (CDR), Frontotemporal dementia rating scale (FTD-CDR)
• Secondary: NfL change in plasma/CSF, brain atrophy rates (MRI)
• Cognitive: Executive function tests, language assessments
• Behavioral: Neuropsychiatric Inventory (NPI), FTD-specific behavioral scales

Research Directions

Key research priorities include: [@jucker2024]

Prognosis

FTD typically progresses with: [@li2024]

• Disease duration: Median survival 6-11 years from symptom onset
• Functional decline: Progressive loss of independence in activities of daily living
• Death: Usually from complications (aspiration, infection, falls)
• Caregiver burden: High due to behavioral disturbances and young onset

Open Questions

See Also

• [Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison](/diseases/mitochondrial-dysfunction-neurodegeneration-comparison)
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Most common neurodegenerative dementia
• [Parkinson's Disease](/diseases/parkinsons-disease) — Another movement disorder with dementia
• [ALS (Amyotrophic Lateral Sclerosis](/diseases/als)) — Shares genetic and pathological features
• [Behavioral Variant FTD (bvFTD](/diseases/behavioral-variant-ftd)) — Most common FTD subtype
• [Semantic Variant PPA](/diseases/semantic-variant-ppa) — FTD subtype affecting language
• [Progressive Supranuclear Palsy (PSP](/diseases/psp)) — Related tauopathy
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — Major FTD pathology
• [MAPT Gene](/proteins/mapt-protein) — Tau gene mutations
• [GRN Gene](/proteins/grn-protein) — Progranulin gene mutations
• [C9orf72 Gene](/proteins/c9orf72-protein) — ALS/FTD expansion gene

External Links

Research Resources

• [Frontotemporal Dementia Research (AFTDC)](https://www.ftdrg.org/) — Research consortium
• [ALLFTD Study](https://www.allftd.org/) — Longitudinal study of FTD and ALS
• [KEGG FTD Pathway](https://www.genome.jp/kegg/pathway.html) — Molecular pathways

Patient & Advocacy Organizations

• [AFTD (Association for Frontotemporal Degeneration)](https://www.theaftd.org/) — Patient support and research advocacy
• [CurePSP](https://www.psp.org/) — Support for PSP, CBD, and FTD

Clinical Trials

• [ClinicalTrials.gov: Frontotemporal Dementia](https://clinicaltrials.gov/ct2/results?cond=Frontotemporal+Dementia) — Current FTD trials

Recent Research (2025-2026)

Tau and TDP-43 Biomarker Advances

Recent studies have advanced our understanding of fluid biomarkers in FTD. Plasma p-tau181 and [p-tau217](/biomarkers/p-tau-217) have shown promise in distinguishing FTD subtypes, with elevated levels in patients with underlying tau pathology compared to TDP-43 pathology.[13] Neurofilament light chain (NfL) continues to serve as a marker of disease progression and treatment response in clinical trials.[14]

Genetic Insights from Large Cohorts

Large-scale genetic studies have refined our understanding of FTD genetics. Whole-genome sequencing studies have identified rare variants in new candidate genes including TMEM163, AP4M1, and SPPL2A.[15] The Genetic Frontotemporal Dementia Initiative (GENFI) continues to characterize pre-symptomatic carriers of MAPT, GRN, and C9orf72 mutations.[16]

Clinical Trial Updates

Several clinical trials are targeting specific molecular pathways in FTD:

• GRN deficiency: Antisense oligonucleotide (ASO) therapies targeting GRN mRNA are in development, with early-stage trials showing promise for increasing progranulin levels[17]
• MAPT pathology: Tau-directed therapies including ASOs and small molecule inhibitors are being evaluated[18]
• C9orf72: Approaches targeting hexanucleotide repeat expansion are in preclinical development[19]

Emerging Therapeutic Approaches

• Antisense oligonucleotides: GRN-targeting ASOs (IONIS-ApoCRx, etc.) showing safety and biomarker engagement in Phase 1/2 trials
• Gene therapy: AAV-mediated gene delivery approaches for GRN and MAPT
• Small molecule modulators: FUS pathology modulators, TDP-43 aggregation inhibitors

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Emerging Therapeutic Targets

Anti-Tau Therapies

Tau-directed approaches are actively being developed for FTLD-tau subtypes: [@ferrari2025]

Tau aggregation inhibitors:

• [LMTM (TRx0237](/therapeutics/lmtx-trx0237)): Blocks tau aggregation, Phase III
• Methylene blue derivatives: Reduce tau oligomer formation
• Small molecule inhibitors: Target tau-tau interaction domains

• [Gosuranemab](/therapeutics/gosuranemab): Anti-tau antibody in trials for PSP (discontinued)
• [Semorinemab](/therapeutics/semorinemab): Targeting tau pathology in FTD subtypes
• [Bepranemab](/therapeutics/bepranemab): MTBR-targeting, Phase II
• [JNJ-63733657](/therapeutics/jnj-63733657): p-tau217 targeting, Phase II

• [BIIB080 (MAPTRx](/therapeutics/biib080-maptrx)): Antisense oligonucleotide reducing MAPT expression, Phase II
• Gene silencing: Reduce mutant tau production in MAPT mutation carriers

TDP-43 Targeted Approaches

Therapies targeting TDP-43 pathology: [@rohrer2025]

ASO approaches:

• C9orf72 ASOs: Reduce toxic RNA foci and dipeptide repeat proteins
• TDP-43 splicing modulators: Restore normal TDP-43 splicing function

• Autophagy enhancers: Boost protein clearance pathways
• Proteasome modulators: Enhance degradation of misfolded proteins

Neuroinflammation Modulation

Anti-inflammatory approaches for FTD: [@jiang2026]

• Microglial inhibitors: CSF1R antagonists reduce microglial proliferation
• NLRP3 inhibitors: Block inflammasome activation
• TNF-α blockade: Anti-TNF approaches in early trials
• Minocycline: Antibiotic with anti-inflammatory properties

Progranulin Replacement

For GRN mutation carriers: [@boxer2026]

• Recombinant progranulin: Protein replacement therapy
• Gene therapy: AAV-mediated GRN delivery
• Small molecule upregulators: Increase endogenous progranulin expression

Neuroprotective Strategies

General neuroprotective approaches: [@zhang2025]

• Antioxidants: Mitochondrial protectants
• Neurotrophic factors: BDNF, GDNF delivery
• Ion channel modulators: Calcium homeostasis
• Metabolic support: Energy enhancement strategies

References